Log in
Enquire now
Promethera Biosciences

Promethera Biosciences

Promethera Biosciences is a biotechnology company developing regenerative medicine treatments for liver diseases.

OverviewStructured DataIssuesContributors

Contents

cellaion.com
promethera.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Biopharmaceutical
Biopharmaceutical
Biology
Biology
Technology
Technology
Medicine
Medicine
Healthcare
Healthcare
Regenerative medicine
Regenerative medicine
Cell therapy
Cell therapy
...
Location
Mont-Saint-Guibert
Mont-Saint-Guibert
0
Belgium
Belgium
‌
Durham, Arkansas
Durham, North Carolina
Durham, North Carolina
B2X
B2B
B2B
CEO
Etienne Sokal
Etienne Sokal
0
Founder
Etienne Sokal
Etienne Sokal
0
AngelList URL
angel.co/company/pr...biosciences
Pitchbook URL
pitchbook.com/profiles.../54142-03
Legal Name
PROMETHERA Biosciences S.A./N.V.
Date Incorporated
2009
Email Address
info@cellaion.com0
Phone Number
+32103943000
Full Address
Durham, North Carolina, United States
Watson & Crick Hill Rue Granbonpre, 11 1435 Mont Saint Guibert Belgium0
Investors
S.R.I.W.
S.R.I.W.
Pegasus Tech Ventures
Pegasus Tech Ventures
0
‌
Mitsui Ventures
Shire (pharmaceutical company)
Shire (pharmaceutical company)
‌
Belgian Sambrinvest
Boehringer Ingelheim
Boehringer Ingelheim
‌
Atmi
...
Founded Date
2009
Total Funding Amount (USD)
103,075,320
Latest Funding Round Date
December 16, 2019
Former CEO
John Tchelingerian
John Tchelingerian
Latest Funding Type
Series D
Series D
Patents Assigned (Count)
2
Wellfound ID
promethera-biosciences
Country
Belgium
Belgium
0

Other attributes

Company Operating Status
Active
Latest Funding Round Amount (USD)
8,400,000
Wikidata ID
Q30269226

Promethera Biosciences is a biotechnology company developing regenerative medicine treatments for liver diseases that is headquartered in Mont-Saint-Guibert, Belgium and was founded in 2009 by Etienne Sokal.

The company is a spin-off of the Universita Catholique de Louvain, and is interested in developing treatments based on allogenic adult stem cell technology. They look to commercialize cell therapy products to treat liver diseases using progenitor cells from healthy human livers. The progenitor cells that Promethera Biosciences are adult liver-derived mesenchymal progenitor cells.

Promethera Biosciences looks to develop new cell and antibody-based therapies for the treatment of liver diseases. The company has developed a cell-based therapy called HepaStem, which has potential to provide novel treatment options for chronic and acute live diseases. This could be successful for Acute-on-Chronic Liver Failure, fibrosis, and non-alcoholic SteatoHepatitis. The HepaStem can be administered intravenously, transported through the bloodstream to the liver, and provide it a chance to repair and regenerate. It reduces inflammation processes as well as fibrogenesis, as it inhibits hepatic stellate cell activation and collagen secretion, and degrades the excessive extracellular matrix.

Another product of Promethera Biosciences is the H2Stem. The H2Stem is used to display a high capacity for homing, in situ differentiation into hepatocytes and repopulation after their transplantation in a model of human xenografts.

The company's third and fourth product are the antibody-based drug candidates which includes the Atrosab and Atrosimab. These products target the pro-inflammatory tumor necrosis factor receptor 1, and blocks its activation by TNF-alpha without interacting with the TNF receptor 2.

Introduction to Promethera Biosciences.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

cGMP Compliance Status for Promethera Biosciences’ Production Site in Durham, NC Confirmed by Health Canada

Business Wire

https://www.businesswire.com/news/home/20180829005229/en/cGMP-Compliance-Status-Promethera-Biosciences%E2%80%99-Production-Site

Web

Promethera BioSciences

https://www.youtube.com/watch?v=jqQj3o9zAOk

October 24, 2016

Promethera Biosciences Announces Investment by ITOCHU Corporation and a Broad Strategic Collaboration to Access the Asian Markets

Business Wire

https://www.businesswire.com/news/home/20190101005030/en/Promethera-Biosciences-Announces-Investment-ITOCHU-Corporation-Broad

Web

Promethera Biosciences official channel

https://www.youtube.com/watch?v=vPwBNdJkoDk

January 24, 2019

Promethera Biosciences Raised €25,33M to Treat Liver Diseases

JULIE LELLOUCHE

https://labiotech.eu/medical/promethera-biosciences-raised-e2533m-treat-liver-diseases/

Web

References

Find more companies like Promethera Biosciences

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.